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the contrast-enhanced MRI imaging. CTV2 encompassed the 
whole brain. Only the PTV1 dose was escalated (planned dose 
escalation: 35 Gy, 40 Gy, 45 Gy, 50 Gy) while the PTV2 dose 
remained the same (30 Gy/3 Gy/fractions). Dose-limiting 
toxicities (DLTs) were defined as any treatment-related non-
hematological adverse effects rated as grade ≥ 3, or any 
hematological toxicity rated as ≥ 4 by CTCAE scale, v. 4.0. 
MTD was exceeded if > 2 of 6 patients in a cohort 
experienced dose-limiting toxicity (DLT).  
Results: 27 consecutive patients (pts) were treated (PTV1 
dose: 35 Gy, 8 pts; 40 Gy, 6 pts; 45 Gy, 6 pts; 50 Gy, 7 pts). 
The number of treated brain lesions was: 1 (17 pts), 2 (4 pts), 
3 (5 pts) and 4 (1 pt). Three pts experienced a DLT: 1 pt (2nd 
dose level) developed a grade 3 skin toxicity, 1 pt had a 
grade 3 neurological toxicity (4th dose level) and 1 pt had a 
brain hemorrhage (4th dose level). Nineteen pts experienced 
cutaneous (17 pts) and/or neurological (10 pts) grade 1-2 
acute toxicity. The response to treatment was evaluable in 
16 pts: 1 pt (6.2%) disease progression, 2 pts (12.5%) stable 
disease, 10 pts (62.5%) partial response and 3 pts (18.8%) 
complete response. Median and 1-year overall survival were 
13 months and 51.9%, respectively. Late toxicity was not 
recorded. 
Conclusions: This is the first prospective trial demonstrating 
that a radiation dose of 50 Gy in 10 fractions can be 
delivered by using a SIB IMRT technique without unacceptable 
toxicity in patients with < 5 brain metastases. A phase II trial 
(ISIDE-BM-2) is in progress to evaluate the response and the 
time to progression. 
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Purpose/Objective: Stereotactic ablative body radiotherapy 
(SABR) is the standard treatment modality for a limited 
number of brain metastases (BM). Several models for survival 
prediction have been published, such as the commonly used 
Recursive Partitioning Analysis (RPA), Golden Grading System 
(GGS), and the Disease Specific Graded Partitioning Analysis 
(DS-GPA). All published models have limitations for 
prediction of survival after SABR for BM: e.g. small proportion 
of patients in the favorable prognostic group, a low 
sensitivity for the identification of patients with long term 
survival, and some models are complex to use (e.g. DS-GPA). 
In this study, a new prognostic model is developed with the 
aim of overcoming above mentioned limitations. 
Materials and Methods: Based on published models and 
clinical practice a new prognostic model was developed. Its 
clinical utility was tested for prediction of early death (<3 
months) and long term survival (>12 months) in 297 patients 
with 1 up to 4 newly diagnosed BM treated with Linac-based 
SABR at our department between July 2004 and July 2014. 
Prescribed dose at the edge of the PTV was in the range of 15 
up to 24Gy in 1 or 3 fractions.  
Results: In the published models the two most important 
prognostic factors were: WHO performance status and 
presence of extracranial metastases. Poor performance 
status only was identified as the poor prognostic group 
according to Dutch guidelines. Remaining patient cohort was 
divided based on the presence of extracranial metastases. 
The developed model is a simplified version of the commonly 
used RPA, and was named Simplified Recursive Partitioning 
Analysis (SRPA). 
- SRPA class I: WHO performance status 0/1 & no extracranial 
metastases 
- SRPA class II: WHO performance status 0/1 & extracranial 
metastases 
- SRPA class III: WHO performance status of 2 or more 
Median age was 63 years and the majority of patients had 
non-small cell lung cancer (64%). The median survival after 
SABR was 9 months, with 3 months-, 1 year-, and 5 years 
survival of respectively 81%, 36%, and 9%. The patient 
distribution was most balanced in the SRPA with 48% of 
patients in the favorable prognostic class (vs 20%-29% in the 
other models, Table 1). Sensitivity for prediction of long-
term survival was highest using the SRPA (56% vs 16-46% in 
other classes). The specificity of predicting 3-months death 
in the poor prognostic class was high in all scores (range 86% 
up to 98%). The SRPA was valid in an external SABR for 1-3 BM 





Conclusions: The SRPA had the highest clinical utility for 
survival prediction after SABR for BM compared to the RPA, 
DS-GPA, and GGS. The SRPA is very simple in use, assembles 
to clinical practice, has a balanced patient distribution 
between the favorable and intermediate group, the highest 
sensitivity for prediction of long term survival, was specific 
for prediction of early death, and was validated in an 
external population. Further research will focus on further 
validation in other BM populations and exploration of the 
predictive value of advanced techniques such as radiomics, 
biomarkers, and statistical modeling. 
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The Artforce  (Adaptive and innovative Radiation Treatment 
FOR improving Cancer treatment outcomE) project is an EU 
7th Frame work funded project. The aims of this project are: 
1. To deliver higher tumour doses by redistributing the 
radiation dose towards highly positive in FDG-PET scans 
areas; 
2. Advanced treatment monitoring, in particular daily cone 
beam CT on the linear accelerator, repetitive FDG-PET 
imaging and electronic portal dosimetry;  
3. To validate specific predictors for tumour response to 
cisplatin and cetuximab and normal tissue complication;   
4. To improve strategies for biological and anatomical 
adaptive optimisation. 
This project includes two on-going randomized clinical trials, 
aiming at dose redistribution in head and neck and lung 
cancer.  
For these trials the following projects are carried out: 
Adaptive radiotherapy: P.I. Jan-Jakob Sonke 
All relevant imaging and planning data for improved outcome 
modelling and data mining were collected to account for 
anatomical changes. A method to update the geometrical 
patient model was developed and validated. Using 
deformable image registration of repeat cone beam CT 
(CBCT) scans acquired during the first part of the treatment, 
the original planning CT is deformed to the average patient 
model.  
Biological adaptive treatment planning P.I. Iuliana Dasu 
Assessment of the tumour responsiveness based on two 
successive FDG-PET scans, one taken at the planning stage, 
before the start of the treatment, and a second one taken 
during the second week of treatment, in relation to the 
delivered dose, was evaluated in 26 NSCLC patients. It 
showed that it is feasible to determine a threshold value for 
the effective radiosensitivity of the patients corresponding to 
good response.   
In vivo dosimetry: P.I Wouter van Elmpt 
Three dimensional (3-D) in-vivo dosimetry as an integrated 
quality assurance (QA) procedure to accurately verify dose 
delivery applicable to all the major teletherapy systems in 
the EU were developed, validated and implemented.  
Biomarkers: P.I. Eric Deutsch and Guido Kroemer 
Tumour biopsies are being collected to predict the sensitivity 
to cisplatin and the radiation response.  During the first 
period of the project we identified pyridoxal kinase (PDXK), 
the enzyme generating bioactive vitamin B6, as a prognostic 
marker in three independent cohorts of non-small cell lung 
carcinoma patients.  
Imaging: P.I. Philippe Lambin 
Visual analysis of 10 head and neck cancer patients showed 
heterogeneous uptake of  89Zr-labelled cetuximab within the 
Gross Tumour Volume (GTV).  An analysis in lung cancer 
patients of the overlap fractions and regions for both FDG- 
and HX4-PET scans revealed a positive correlation between 
FDG and HX4 uptake parameters on a GTV level.   
Lung cancer trial: P.I. Jose Belderbos and Dirk de Ruysscher 
End of 2014, 118 patients were registered and 78 
randomized.  
The toxicity assessed in November 2014 did not reveal 
unexpected or serious adverse events.   
Head and Neck cancer trial. P.I. Olga Hamming 
End of 2014, 32 patients have been randomized. 
Unfortunately, the supply of cetuximab free of charge was 
stopped (after May 2014) which necessitated a significant 
adaptation of the protocol.  
The toxicity analysis in March 2014 based upon the first 15 
patients demonstrated that all patients could finish their 
radiation treatment without delay. Acute toxicities are as 
expected from a curative chemoradiation treatment in the 
head and neck area. 
Participating centres: The Netherlands Cancer Institute, 
Amsterdam; Karolinska Institutet, Stockholm; Maastro Clinic, 
Maastricht; Val d’Hebron Hospital, Barcelona; INSERM, Paris; 
RaySearch, Stockholm; Christie Hospital, Manchester; Institut 
Gustave Roussy, Villejuif. 
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In the age of personalized medicine, information about the 
tumour characteristics guiding treatment decisions prior to 
and early during therapy is of crucial importance. While local 
extension of head and neck squamous cell carcinoma (HNSCC) 
is mainly assessed by physical examination and anatomical 
imaging, unfavourable tumour features such as hypoxia, 
proliferation rate and intrinsic radio-resistance are not 
reliably depicted. Therefore, the added value of molecular 
imaging with positron emission tomography (PET) is 
increasingly explored in head and neck tumours. Integration 
of PET techniques into therapy selection and adaptation 
strategies, as well as radiation treatment planning for 
HNSCC, can serve several purposes. First, pre-treatment 
assessments can steer decisions about radiotherapy 
modifications or combinations with other modalities. Second, 
biology-based objective functions can be introduced to the 
radiation treatment planning process by co-registration of 
molecular imaging with planning CT-scans. Thus, customized 
heterogeneous dose distributions can be generated with 
escalated doses to tumour subvolumes where radiotherapy 
resistance mechanisms are most prevalent. Third, monitoring 
of temporal and spatial variations in these radiotherapy 
resistance mechanisms early during the course of treatment 
can discriminate responders from non-responders. With such 
information available shortly after the start of treatment, 
modifications can be implemented or the radiation treatment 
plan can be adapted tailing the biological response pattern. 
The most commonly applied PET tracer - 18FDG - highlights 
volumes of increased cellular metabolism, but requires 
careful interpretation due to uptake in non-malignant tissues 
or peritumoral inflammation. Several studies have 
demonstrated a prognostic value of 18FDG PET imaging before 
and during therapy based on quantification or volumetric 
characteristics. Ongoing investigations evaluate utilization of 
18FDG signal as a basis for radiotherapy dose redistribution. 
A number of PET tracers associated with tumour cell hypoxia, 
e.g., 18FMISO and 18FAZA, have shown prognostic value and 
may guide individualized therapy, i.e., the addition of 
hypoxia-modulating agents or dose-escalation to radio-
resistant tumour subvolumes. 
18FLT-PET can be used repetitively to characterize tumour 
proliferation before and during treatment, facilitating 
adaptive radiotherapy and other tailored treatment 
strategies. Antibody-based PET tracers such as 89Zr-labeled 
cetuximab, specific to the epidermal growth factor receptor 
(EGFR), can be utilized for assessment of presence, 
